Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

European Journal of Cancer

Volumn 48, Issue 12, 2012, Pages 1774-1780

  Rodríguez, Javier ^a   Zarate, Ruth ^b   Bandres, Eva ^b   Boni, Valentina ^a   Hernández, Amaia ^a   Sola, Jesus Javier ^a   Honorato, Beatriz ^b   Bitarte, Nerea ^b   García Foncillas, Jesus ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cetuximab; Colorectal cancer; EGFR; Fc R polymorphisms; KRAS

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CODON; DISEASE CONTROL; DISEASE CONTROL RATE; DRUG EFFICACY; FC GAMMA RECEPTOR GENE; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; ONCOGENE K RAS; ONCOGENE N RAS; PHOSPHATIDYLINOSITOL 3 KINASE GENE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG;

EID: 84864131126     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.01.007     Document Type: Article

References (32)

1. F. Di Fiore, R. Sesboüé, P. Michel, J.C. Sabourin, and T. Frebourg Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer Br J Cancer 103 12 2010 1765 1772
2. T.J. Kruser, and D.L. Wheeler Mechanisms of resistance to HER family targeting antibodies Exp Cell Res 316 2010 1083 1100
3. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of Cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
4. A. Sartore-Bianchi, K. Bencardino, and F. Di Nicolantonio Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer Target Oncol 5 2010 19 28
5. G. Perkins, A. Lièvre, and C. Ramacci Additional value of EGFR downstream signaling phosphoproteins expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer Int J Cancer 127 2010 1321 1331
6. P. Laurent-Puig, A. Cayre, and G. Manceau Analysis of PTEN, BRAF, and EGFR status in determining benefit from Cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 2009 5924 5930
7. L.X. Qiu, C. Mao, and J. Zhang Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with Cetuximab: a meta-analysis of 22 studies Eur J Cancer 46 2010 2781 2787
8. J.R. Desjarlais, G.A. Lazar, E.A. Zhukovsky, and S.Y. Chu Optimising the engagement of the immune system by anti-tumor antibodies: an engineer's perspective Drug Discov Today 12 2007 898 910
9. F. Bibeau, E. Lopez-Crapez, and F. Di Fiore Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with Cetuximab plus irinotecan J Clin Oncol 27 2009 1122 1129
10. G. Cartron, L. Dacheux, and G. Salles Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaR-IIIa gene Blood 99 2002 754 758
11. A. Musolino, N. Naldi, and B. Bortesi Immunoglobulin G fragments C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with Her-2/neu positive metastatic breast cancer J Clin Oncol 26 2008 1789 1796
12. W. Zhang, M. Gordon, and A.M. Schultheis FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent Cetuximab J Clin Oncol 25 2007 3712 3718
13. J. Pander, H. Genderblom, and N.F. Antonini Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of Cetuximab in KRAS wild-type metastatic colorectal cancer Eur J Cancer 46 2010 1829 1834
14. P. Correale, M. Marra, and C. Remondo Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhances their susceptibility to EGFR-targeted antibody-dependent cell-mediated cytotoxicity Eur J Cancer 46 2010 1703 1711
15. M. Schlaeth, S. Berger, and S. Derer Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells Cancer Sci 101 2010 1080 1088
16. W.L. Van der Pol, M.D. Jansen, and W.J. Sluiter Evidence for non-random distribution of Fcγ receptor genotype combinations Immunogenetics 55 2003 240 246
17. F. Di Fiore, E. Van Cutsem, and P. Laurent-Puig Role of KRAS mutation in predicting response, progression-free survival and overall survival in irinotecan-refractory patients treated with Cetuximab plus irinotecan for metastatic colorectal cancer: analysis of 281 individual data from published series J Clin Oncol 26 Suppl. 2008 [abstr. 4035]
18. S. Siena, M. Peeters, and E. Van Cutsem Association of progression-free survival with patien-reported outcomes and survival. Results from a randomised phase 3 trial of Panitumumab Br J Cancer 97 2007 1469 1474
19. T. Maughan, R. Adam, and C. Smith Addition of Cetuximab to oxaliplatin-based combination chemotherapy in patients with KRAS wild-type advanced colorectal cancer: a randomised superiority trial (MRC COIN) Eur J Cancer 7 Suppl. 2009 4 [abstr. 6LBA]
20. N. Moosmann, L.F. Von Weikersthal, and U. Vehling-Kaiser Cetuximab plus capecitabine and irinotecan compared with Cetuximab plus capecitabine and oxaliplatin as first line treatment for patients with metastatic colorectal cancer: AIO KRK-0104. A randomized trial of the german AIO CRC study group J Clin Oncol 29 2011 1050 1058
21. S. DallÓzzo, S. Tartas, and G. Paintaud Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship Cancer Res 64 2000 4664 4669
22. G.L. Beatty, E.G. Chiorean, and M.P. Fishman CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
23. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 2000 443 446
24. E.M. Levy, G. Sycz, and J. Martín Arriaga Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells Innate Immunity 15 2009 91 100
25. K. Kono, A. Takahashi, and F. Ichihara Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer Cancer Res 62 2002 5813 5817
26. A.P. De Souza, and C. Bonorino Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses Expert Rev Anticancer Ther 9 2009 1317 1332 Review
27. R. Maréchal, J. De Schutter, and N. Nagy Putative contribution of CD56 positive cells in Cetuximab treatment efficacy in first-line metastatic colorectal cancer patients BMC Cancer 10 2010 340 350
28. G. Garrido, P. Lorenzano, and B. Sánchez T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies Cancer Immunol Immunother 56 11 2007 1701 1710
29. F. Ghiringhelli, C. Menard, and P.E. Puig Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 5 2007 641 648
30. A. Tesniere, F. Schlemmer, and V. Boige Immunogenic death of colon cancer cells treated with oxaliplatin Oncogene 29 4 2010 482 491
31. M. Hara, H. Nakanishi, and K. Tsujimura Interleukin-2 potentiation of Cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity Cancer Sci 99 2008 1471 1478
32. R. Geva, V. Jensen B, and G. Fountzilas An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on Cetuximab efficacy JCO 29 2011 [abstr. 3528]